Wed, 25th Apr 2018 13:41
LONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.
This, it said, follows a US patent which was granted for VAL201, a proposed prostate cancer treatment currently in clinical trials, in March.
ValiRx said the patent grant was a "major" milestone for the company, with the treatment now having patent cover across much of the globe and in all major markets.
Shares were up 2.1% on Wednesday at 3.19 pence each.
ValiRx PLC - life sciences company focused on early-stage cancer therapeutics and women's health - Notes that its subsidiary Inaphaea BioLabs Limited ...
(Alliance News) - Stock prices in London closed higher on Monday, with investors optimistic that interest rate cuts might be around the corner.
(Alliance News) - ValiRx PLC on Monday noted that the peptide nanoparticle formation Cytolytix received a Knowledge Transfer Voucher grant in conjunct...
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
ValiRx (VAL)